주식/증권
📈 긍정적
BioStem Technologies Reports Second Quarter 2026 Financial Results
요약
Generates 29% sequential revenue growth, increasing to $7.9 million;Raises full-year 2026 revenue guidanceUplists to Nasdaq Capital Market POMPANO BEACH, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the second quarter ended June 30, 2026. Recent Corporate Highlights Completed the